Skip to main content
letter
. 2020 Jul 14;93(1):155–157. doi: 10.1002/jmv.26255

Table 1.

Baseline demographic, clinical, and treatment characteristics of patients

Variable Patient 1 Patient 2
Age, y 51 63
Sex M M
BMI, kg/m2 22 18
Race AA AA
Symptoms at presentation
Fever No No
Dyspnea Yes Yes
Cough No Yes
Nausea/emesis Yes No
Myalgias Yes No
Vital signs baseline (peak)
Temp 98.8 (100.8) 98.3 (98.7)
RR, per min 17 (25) 17 (20)
HR, per min 66 (99) 94 (110)
Oxygen Saturation 86 (85) 90 (90)
SBP, mm Hg 153 (180) 130 (143)
Baseline (peak) lab. values
WBC, ×109/L 5.1 (11) 2.4 (5.7)
Lymphocytes, ×109/L 18 34 (49)
Hemoglobin, g/dL 12.7 (12.9) 12.8 (13)
Platelets, ×109/L 88 (155) 454 (459)
AST, units/L 108 (131) 53
ALT, units/L 78 (84) 43
ALP, IU/L 135 (135) 92
BUN, mg/dL 11 (24) 33
Creatinine, mg/dL 0.8 (0.9) 1.6
CRP, mg/L 4.95 (4.95)
ESR, h 131 (131)
Ferritin, ng/mL 742 (1264) 2292 (2292)
Superimposed infection Streptococcus pneumoniae None
HAART regimen None None
Immunological profile
CD4 cell count 10.2 116.3
HIV RNA PCR copies 26 900 2 540 000
Management
Hydroxychloroquine NA NA
Corticosteroids NA NA
Tocilizumab NA NA
Antibiotics Azithromycin, bactrim, zosyn Bactrim
Other Zinc sulfate, vitamin C
Outcomes
Length of hospitalization, d 10 7
ICU admission, n (%) 0 (0) 0 (0)
Mechanical ventilation, n (%) 0 (0) 0 (0)
In‐hospital death, n (%) 0 (0) 0 (0)
Readmission 0 (0) 0 (0)

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, Body mass index; BUN, blood urea nitrogen; CD4, cluster of differentiation 4; CRP, C reactive protein; HAART, highly active antiretroviral therapy; HIV RNA PCR, human immunodeficiency virus ribonucleic acid polymerase chain reaction; HR, heart rate; ICU, intensive care unit; RR, respiratory rate; SBP, systolic blood pressure; SR, erythrocyte sedimentation rate; WBC, white blood cell count.